With the introduction of Amgen’s Amjevita, AbbVie’s Humira loses its 2 decades of exclusivity. A slate of other Humira biosimilars are set to drop this year as well, with prices set to drop due to competition. However, the changes may be slow to take effect, as several factors are set to complicate […]
Orphan Drugs Lead Specialty Medication FDA Approvals
Specialty medications currently lead the charts in terms of new drug approvals by the US Food and Drug Administration (FDA). On top of the heap are orphan drugs, treatments for rare diseases or those with no current therapeutics. In a new Pharmacy Practice News article, learn more about the orphan […]
First Humira Biosimilar Finally Hits Pharmacies with Two Price Points
After a 20-year monopoly on the market, AbbVie’s Humira has lost exclusivity with the entrance of Amgen’s biosimilar, Amjevita. This marks the beginning of the end of the $114 billion rheumatoid arthritis drug’s dominance, propped up by widely critiqued patent thicketing. The biosimilar will follow […]
Boehringer Ingelheim Reveals Positive Trial Results for Rare Psoriasis Therapeutic
Boehringer Ingelheim revealed new results from its Phase IIb EFFIOSAYIL 2 trial that shows its new antibody-based therapeutic Spevigo can prevent flare-ups in a rare and severe form of psoriasis, generalized postular psoriasis (GPP). The drug is the first treatment to be approved for the disabling […]
FDA Approves Two New Treatments for Breast Cancer and Lymphoma
Eli Lilly and the Menarini Group have both gotten the nod from the US Food and Drug Administration (FDA) for their new cancer medications. Lilly’s therapeutic for relapsed or refractory mantle cell lymphoma, called Jaypirca, is only the fourth drug of its kind approved by the agency. It will cost […]
US Senator Elizabeth Warren Asks FTC to Investigate Two Pharma Mergers
US Senator Elizabeth Warren (D-MA) has expressed her concerns regarding two upcoming major pharma mergers, calling for the Federal Trade Commission (FTC) to investigate them. The two mergers are Amgen’s planned acquisition of Horizon Therapeutics for $28 billion and Indivior’s $145 million buyout of […]
Pharma Prepares for Bernie Sanders as US Senate Health Committee Chairman
US Senator Bernie Sanders (I-VT) has decried prescription drug prices and insurer practices throughout his political career. Now, as chairman of the Senate health committee, he will guide hearings and investigations into major pharma companies, pharmacy benefit managers (PBMs), and insurers. […]
South Korean Pharma Industry Group Asks Government for Industry Steering Committee
According to the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA), an industry group comprised of pharma companies based in South Korea, the nation should establish a steering committee helmed by industry leaders. The committee, according to KPBMA Chairman Won Hee-mok, would […]
Almost 1,000 US Drug Prices Hiked So Far in 2023
Drugmakers have raised the price of almost 1,000 prescription drugs this past month alone. These price hikes are anything but transparent for patients, as they are often obfuscated by complicated rebate schemes and reimbursement practices. Some lay the blame on upcoming provisions of the Inflation […]
Bristol Myers Reveals Positive Phase II Data for Leukemia CAR-T Cell Therapy Breyanzi
Bristol Myers Squibb has announced new clinical trial data for its leukemia CAR-T cell therapy Breyanzi. The data shows that the therapy has met its primary endpoint in the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL), beating standard care in complete […]